WHAT AND WHY?

HOW AND WITH WHOM?

RESULTS, IMPACT AND RECOMMENDATIONS

What next?

Needle-free

diabetes management

Fast interstitial fluid sampling for non-invasive diabetes management

Dr. Alejandro García Pérez, PhD.

• Over 400 MILLION people suffer from diabetes.

• Over 1.9 BILLION people are overweight (at risk of getting diabetes).

• Our technology promotes better management and prevention of

diabetes by enabling convenient, non-invasive and painless glucose

monitoring.

We developed a patent pending solution to extract interstitial fluid from the

dermis in a painless and non-invasive manner. The concentration of

glucose in interstitial fluid is measured using state-of-the-art biosensors,

and it correlates with blood glucose.

Key collaborators and stakeholders: University of Helsinki, Åbo Akademi

University, Business Finland, and IoT Forge Foundation. The project

involved top experts from Finland, México, Russia and Canada.

Results from a pilot study in healthy individuals showed that our technology meets the level of analytical accuracy required for regulatory clearance.

This project has created a compelling foundation to establish GlucoModicum Oy (Y-tunnus: 2900506-7).

Public Relations & Eco-system engagement with high impact audiences.

Finalize the prototype

Start early-phase clinical trials

Apply for regulatory clearance

Continue engagement with technology and pharma companies

• Patent pending technology for extraction of dermal interstitial fluid

is tested in humans.

• Initial prototype built. We demonstrated that the solution can be

implemented into a small formfactor.

• Final solution encompasses our novel interstitial fluid sampling

method, state-of-the-art biosensors and a convenient user

interface.

Figure 1. Key achievements

More information:

Alejandro García Pérez

alejandro.garciaperez@helsinki.fi

Partners:

From academic research to scientific and societal impact